AI-Guided Pacing for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how well an AI-assisted pacing method for the heart, specifically AI-assisted Left Bundle Branch Area Pacing, compares to the usual method in helping people with heart failure. The researchers aim to determine if AI can improve heart function and overall health outcomes. Participants may qualify if they have heart failure with a specific heart function measurement (less than 50% efficiency) and are on standard heart failure treatments. As an unphased trial, this study offers a unique opportunity to contribute to cutting-edge research that could enhance future heart failure treatments.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it requires that you are already on optimized medical therapy for heart failure.
What prior data suggests that AI-assisted Left Bundle Branch Area Pacing is safe for heart failure patients?
Research has shown that Left Bundle Branch Area Pacing (LBBAP) is a relatively safe treatment for heart issues. Studies indicate that LBBAP offers advantages over other pacing methods, particularly for patients with heart failure. However, there is a 12% risk of developing pacing-induced cardiomyopathy, a heart muscle disease caused by pacing. This risk necessitates careful selection of candidates for this treatment.
The AI-assisted version of LBBAP under testing aims to enhance its effectiveness. Although specific safety data for the AI-guided method is not yet available, traditional LBBAP is generally well-tolerated. Prospective trial participants may find this information helpful in understanding the potential safety of the treatment.12345Why are researchers excited about this trial?
Researchers are excited about AI-assisted Left Bundle Branch Area Pacing for heart failure because it introduces artificial intelligence to improve the precision of pacemaker placements. Unlike traditional pacemakers, which rely on fixed settings, this AI-guided approach can dynamically adjust pacing based on real-time data from the patient's heart, potentially improving heart function and patient outcomes. This innovative use of AI could lead to more personalized treatment strategies, offering hope for enhanced quality of life for those with heart failure.
What evidence suggests that AI-assisted Left Bundle Branch Area Pacing is effective for heart failure?
This trial will compare AI-assisted Left Bundle Branch Area Pacing (LBBAP) with a control treatment for heart failure. Research has shown that AI assistance with LBBAP could benefit people with heart failure. AI-guided pacing uses artificial intelligence to adjust heart stimulation. Studies have found that LBBAP can lower the risk of worsening heart failure and reduce the chance of death by better coordinating heartbeats. AI guidance might enhance these benefits by fine-tuning the pacing. Early results suggest this method can improve heart function and quality of life for heart failure patients.12567
Who Is on the Research Team?
Fatima Ezzeddine
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for adults over 18 with heart failure, where the heart's pumping strength (LVEF) is below 50%. They must have a specific ECG pattern or expect to need significant pacemaker use. Participants should be on stable heart medications but not pregnant or unable to attend follow-up appointments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo AI-guided or conventional LBBAP procedure
Follow-up
Participants are monitored for CRT response and clinical outcomes
What Are the Treatments Tested in This Trial?
Interventions
- AI-assisted Left Bundle Branch Area Pacing
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor